Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024) · Cardiovascular Therapeutics · n=0
Study Profile
- Design
- narrative systematic review of randomized controlled trials comparing heparin and bivalirudin anticoagulation in patients undergoing PCI for STEMI, NSTEMI, and unstable angina (Tangshan Gongren Hospital, China; Wuhan University; Harvard T.H. Chan)
- Sample size (n)
- 0
- Intervention
- Bivalirudin (synthetic hirudin-derived direct thrombin inhibitor) anticoagulation during PCI
- Comparator
- Unfractionated heparin (standard reference anticoagulant)
- Primary endpoint
- Composite of efficacy (ischemic events) and safety (bleeding events) outcomes from major RCTs
- Primary result
- Bivalirudin generally associated with lower bleeding rates than heparin in PCI for ACS; ischemic outcome equivalence varies by trial and ACS subtype; review reinforces clinical equipoise in some patient subgroups; demonstrates how synthetic hirudin-derivative pharmacology is studied via rigorous Phase-III pathways
- Follow-up duration
- Variable across cited RCTs (typically 30 days to 1 year)
- PMID
- 39749045
Key Findings
- Bivalirudin generally associated with lower bleeding than heparin in PCI for ACS
- Trial-by-trial heterogeneity in ischemic-event outcomes
- Bivalirudin is a synthetic hirudin derivative (Angiomax) with established FDA approval
- Demonstrates the drug-regulatory pathway distinct from K040187 device pathway
- Useful pedagogical reference for explaining FDA drug vs FDA device distinctions
Limitations
- Narrative synthesis without quantitative meta-analysis
- Cited RCTs span multiple decades and PCI eras
- Generalization across STEMI / NSTEMI / unstable angina subgroups limited
- No new primary data
- Not directly applicable to whole-leech hirudotherapy
Clinical Implications
Wang 2024 provides contemporary clinical-pharmacology context for bivalirudin — the synthetic hirudin derivative — within interventional cardiology. For ASH, the review serves as a regulatory and educational reference for distinguishing FDA-approved drug indications (synthetic hirudin derivatives) from the FDA K040187 device indication (whole-leech therapy). No direct US hirudotherapy clinical-practice implications.
Related Trials
Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification
Merlino G, Carbone S, Servillo G, Marletta DA (2020)
Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial
Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)
Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review
Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)
Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction
Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)